The Use of FDG-PET in Patient With Hodgkin Lymphoma: a Population Based Study From Northern Italy

The Use of FDG Positron Emission Tomography (PET)in Patient With Hodgkin Lymphoma (HL) in the Real World: a Population Based Study From Northern Italy

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01248000

Enrollment

136

Registered

2010-11-25

Start date

2009-05-31

Completion date

2010-05-31

Last updated

2010-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Histologically Confirmed Classical Hodgkin Lymphoma According to the Current World Health Organisation Classification

Keywords

Hodgkin lymphoma, FDG-PET, prognostic factor, clinical trial

Brief summary

Positron Emission Tomography (PET) represents a step forward in the definition of response to therapy in patients with Hodgkin Lymphoma (HL). In particular the use of PET for the early assessment of response has been described as the most important tool for predicting the risk of disease progression. As no data are available to support the use of early assessment of response for adapting and modifying subsequent treatment, the use of PET should be limited only to patients enrolled in clinical trials. Irrespective of recommendations PET scanning is included in the current management of patients with HL at baseline, mid treatment, end of treatment, and follow-up. So far no study has been performed to verify how PET is currently used in the clinical setting and to assess if and how results of PET scanning are used for supporting treatment and clinical decisions.

Interventions

PROCEDUREFDG-PET

PET interpretation is based on a site-to-site comparison of FDG uptake both before and after chemotherapy (qualitative approach), according to the criteria defined by Cheson (2008)

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Histologically confirmed classical Hodgkin lymphoma according to the current World Health Organisation Classification (nodular sclerosis, mixed cellularity, lymphocyte rich, lymphocyte depleted). 2. Clinical stage I-IV. 3. No previous chemotherapy, radiotherapy or other investigational drug for HL.

Exclusion criteria

1\. None.

Design outcomes

Primary

Measure	Time frame
Progression-free survival	within 1 month after end of treatment
Overall survival	within 1 month after end of treatment
Disease-free survival	within 1 month after end of treatment

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026